<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">37316861</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement.</ArticleTitle><Pagination><StartPage>41</StartPage><MedlinePgn>41</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">41</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-023-00938-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Flavivirus causes many serious public health problems worldwide. However, licensed DENV vaccine has restrictions on its use, and there is currently no approved ZIKV vaccine. Development of a potent and safe flavivirus vaccine is urgently needed. As a previous study revealed the epitope, RCPTQGE, located on the bc loop in the E protein domain II of DENV, in this study, we rationally designed and synthesized a series of peptides based on the sequence of JEV epitope RCPTTGE and DENV/ZIKV epitope RCPTQGE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Immune sera were generated by immunization with the peptides which were synthesized by using five copies of RCPTTGE or RCPTQGE and named as JEV-NTE and DV/ZV-NTE<sub>.</sub> Immunogenicity and neutralizing abilities of JEV-NTE or DV/ZV-NTE-immune sera against flavivirus were evaluated by ELISA and neutralization tests, respectively. Protective efficacy in vivo were determined by passive transfer the immune sera into JEV-infected ICR or DENV- and ZIKV-challenged AG129 mice. In vitro and in vivo ADE assays were used to examine whether JEV-NTE or DV/ZV-NTE-immune sera would induce ADE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Passive immunization with JEV-NTE-immunized sera or DV/ZV-NTE-immunized sera could increase the survival rate or prolong the survival time in JEV-challenged ICR mice and reduce the viremia levels significantly in DENV- or ZIKV-infected AG129 mice. Furthermore, neither JEV -NTE- nor DV/ZV-NTE-immune sera induced antibody-dependent enhancement (ADE) as compared with the control mAb 4G2 both in vitro and in vivo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We showed for the first time that novel bc loop epitope RCPTQGE located on the amino acids 73 to 79 of DENV/ZIKV E protein could elicit cross-neutralizing antibodies and reduced the viremia level in DENV- and ZIKV-challenged AG129 mice. Our results highlighted that the bc loop epitope could be a promising target for flavivirus vaccine development.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Li-Chen</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli County, 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Chia-Lo</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chang-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiao-Wen</ForeName><Initials>QW</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Kuo-Chou</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Family Dentistry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Dentistry, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lien</LastName><ForeName>Shu-Pei</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli County, 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ren-Jye</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>National Mosquito-Borne Diseases Control Research Center, National Health Research Institute, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Ching-Len</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-5745-130X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan. chinglen@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli County, 35053, Taiwan. chinglen@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Mosquito-Borne Diseases Control Research Center, National Health Research Institute, Miaoli, Taiwan. chinglen@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 109-2320-B-400-021</GrantID><Agency>Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>MOST 105-2628-B-016-002-MY2</GrantID><Agency>Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>MOST 109-2320-B-016-012</GrantID><Agency>Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>NHRI-110A1-MRCO-08212101</GrantID><Agency>National Health Research Institutes</Agency><Country/></Grant><Grant><GrantID>MAB-110-104</GrantID><Agency>Ministry of National Defense Medical Affairs Bureau</Agency><Country/></Grant><Grant><GrantID>MND-MAB-C04-111016</GrantID><Agency>Ministry of National Defense Medical Affairs Bureau</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="Y">Zika Virus Infection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="Y">Zika Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue virus</Keyword><Keyword MajorTopicYN="N">Envelop protein domain II</Keyword><Keyword MajorTopicYN="N">Flavivirus vaccine</Keyword><Keyword MajorTopicYN="N">Japanese encephalitis virus</Keyword><Keyword MajorTopicYN="N">Neutralizing epitope</Keyword><Keyword MajorTopicYN="N">Zika virus</Keyword></KeywordList><CoiStatement>All authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37316861</ArticleId><ArticleId IdType="pmc">PMC10265553</ArticleId><ArticleId IdType="doi">10.1186/s12929-023-00938-y</ArticleId><ArticleId IdType="pii">10.1186/s12929-023-00938-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lindenbach BD, Thiel H-J, Rice CM. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley CM, editors. Fields virology. 5. Philadelphia: Lippincot William &amp; Wilkins; 2011. pp. 1101&#x2013;1151.</Citation></Reference><Reference><Citation>Wilder-Smith A, et al. Dengue. Lancet. 2019;393(10169):350&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">30696575</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">21219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen LR, et al. Zika virus. N Engl J Med. 2016;374(16):1552&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pubmed">27028561</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos T, et al. Zika virus and the Guillain-Barre syndrome&#x2014;case series from seven countries. N Engl J Med. 2016;375(16):1598&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">27579558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoen B, et al. Pregnancy outcomes after ZIKV infection in French territories in the Americas. N Engl J Med. 2018;378(11):985&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">29539287</ArticleId></ArticleIdList></Reference><Reference><Citation>Baud D, et al. An update on Zika virus infection. Lancet. 2017;390(10107):2099&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pubmed">28647173</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LJ. Tetravalent dengue vaccine: a review in the prevention of dengue disease. Drugs. 2016;76(13):1301&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">27506852</ArticleId></ArticleIdList></Reference><Reference><Citation>Norshidah H, Vignesh R, Lai NS. Updates on dengue vaccine and antiviral: where are we heading? Molecules. 2021;26(22):6768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620506</ArticleId><ArticleId IdType="pubmed">34833860</ArticleId></ArticleIdList></Reference><Reference><Citation>White LJ, et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) PLoS Negl Trop Dis. 2021;15(3):e0009258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990299</ArticleId><ArticleId IdType="pubmed">33711074</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kim J, Jang YS. Current status and perspectives on vaccine development against dengue virus infection. J Microbiol. 2022;60(3):247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853353</ArticleId><ArticleId IdType="pubmed">35157223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilken L, Rimmelzwaan GF. Adaptive immunity to dengue virus: slippery slope or solid ground for rational vaccine design? Pathogens. 2020;9(6):470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350362</ArticleId><ArticleId IdType="pubmed">32549226</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE, Jr, et al. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005;79(9):5516&#x2013;5528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1082773</ArticleId><ArticleId IdType="pubmed">15827166</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, et al. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, et al. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010;9(2):137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109025</ArticleId></ArticleIdList></Reference><Reference><Citation>Thisyakorn U, Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014;2(1):3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991153</ArticleId><ArticleId IdType="pubmed">24757522</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybakken GE, et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. 2005;437(7059):764&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095628</ArticleId><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11(5):522&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458527</ArticleId><ArticleId IdType="pubmed">15852016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166(4):1016&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983199</ArticleId><ArticleId IdType="pubmed">27475895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520(7545):109&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">25581790</ArticleId></ArticleIdList></Reference><Reference><Citation>Widman DG, Baric RS. Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design? Expert Rev Vaccines. 2015;14(1):5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25249440</ArticleId></ArticleIdList></Reference><Reference><Citation>Messer WB, et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci USA. 2014;111(5):1939&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918811</ArticleId><ArticleId IdType="pubmed">24385585</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994874</ArticleId><ArticleId IdType="pubmed">27339099</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagbami AH, et al. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios. 1987;49(196):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">3028713</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Porterfield JS, O'Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg. 1980;29(4):638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">6157332</ArticleId></ArticleIdList></Reference><Reference><Citation>Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">27417494</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA. 2016;113(28):7852&#x2013;7857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948328</ArticleId><ArticleId IdType="pubmed">27354515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardina SV, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5714274</ArticleId><ArticleId IdType="pubmed">28360135</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013;4(6):e00873-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870244</ArticleId><ArticleId IdType="pubmed">24255124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, et al. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2019;19(1):e31&#x2013;e38.</Citation><ArticleIdList><ArticleId IdType="pubmed">30195995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C-Y, et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis. 2013;7(9):e2432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference><Reference><Citation>Simanjuntak Y, et al. Ebselen alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. PLoS Pathog. 2018;14(2):e1006854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814061</ArticleId><ArticleId IdType="pubmed">29447264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh MS, et al. Detection and quantification of dengue virus using a novel biosensor system based on dengue NS3 protease activity. PLoS ONE. 2017;12(11):e0188170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697845</ArticleId><ArticleId IdType="pubmed">29161301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, et al. A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in mice. Virus Res. 1996;44(1):45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873412</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19(5):696&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">27158114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen LC, et al. Neurovirulent flavivirus can be attenuated in mice by incorporation of neuron-specific microRNA recognition elements into viral genome. Vaccine. 2013;31(49):5915&#x2013;5922.</Citation><ArticleIdList><ArticleId IdType="pubmed">22008823</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope. Structure. 2018;26(1):51&#x2013;59.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29249606</ArticleId></ArticleIdList></Reference><Reference><Citation>Puerta-Guardo H, et al. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains. J Gen Virol. 2010;91(Pt 2):394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">19828759</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan YC, et al. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis. 2012;6(9):e1834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459827</ArticleId><ArticleId IdType="pubmed">23029592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla R, et al. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. EBioMedicine. 2020;60:102991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501058</ArticleId><ArticleId IdType="pubmed">32949997</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsitis SJ, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820409</ArticleId><ArticleId IdType="pubmed">20168989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010;7(2):128&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824513</ArticleId><ArticleId IdType="pubmed">20153282</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, et al. Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice. J Virol. 2015;89(11):5847&#x2013;5861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442448</ArticleId><ArticleId IdType="pubmed">25787279</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargos VN, et al. In-depth characterization of congenital Zika syndrome in immunocompetent mice: antibody-dependent enhancement and an antiviral peptide therapy. EBioMedicine. 2019;44:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6604363</ArticleId><ArticleId IdType="pubmed">31130472</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>